CSTL News and Press, Castle Biosciences Inc. From 05/15/24

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:...

In collaboration with leading GI experts, Castle has also planned several educational sessions at DDW 2024, including a product theater and two American Society for Gastrointestinal Endoscopy (ASGE) theater talks Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health throug...

This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected...

Oral presentation at ARVO shares ground-breaking findings from the ongoing Collaborative Ocular Oncology Group (COOG) study 2 (COOG2) of patients with uveal melanoma (UM) Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care...

2024-05-04 05:45:21 ET Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Conference Call May 02, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Founder & Director Frank Stokes - CFO ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the utility of its DecisionDx-SCC test in patients with high-risk cutaneous squamous cell carcinoma (SCC) tumors located on the head and n...

2024-05-02 16:27:49 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosciences Financial information for Castle Biosc...

Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $ 255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET Castle Bioscie...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-01 17:20:55 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosciences Financial information for Castle Biosc...